BMO Capital Markets Trims Alnylam Pharmaceuticals (ALNY) Target Price to $160.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective cut by investment analysts at BMO Capital Markets from $165.00 to $160.00 in a research note issued to investors on Friday. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 38.03% from the stock’s previous close.

Several other equities analysts have also recently issued reports on ALNY. FBR & Co started coverage on Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 price target on the stock. B. Riley started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, November 1st. They set a “buy” rating and a $240.00 price target on the stock. Piper Jaffray Companies reiterated an “overweight” rating and set a $14.71 price target (down from $188.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 2nd. Needham & Company LLC reiterated a “buy” rating and set a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Finally, Cowen reiterated an “outperform” rating and set a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $124.54.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down $0.40 during mid-day trading on Friday, hitting $115.92. The stock had a trading volume of 1,304,954 shares, compared to its average volume of 887,777. Alnylam Pharmaceuticals has a one year low of $40.93 and a one year high of $147.63. The firm has a market cap of $11,400.00, a PE ratio of -22.08 and a beta of 2.68. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The firm had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter last year, the business posted ($1.32) earnings per share. The firm’s revenue for the quarter was up 116.6% compared to the same quarter last year. sell-side analysts predict that Alnylam Pharmaceuticals will post -5.29 EPS for the current year.

In other news, SVP Laurie Keating sold 6,249 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael Mason sold 36,745 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the transaction, the vice president now owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock worth $28,667,017 over the last 90 days. Insiders own 4.30% of the company’s stock.

Several hedge funds have recently modified their holdings of ALNY. Prudential Financial Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 200 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Alnylam Pharmaceuticals by 5.0% during the second quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock valued at $30,072,000 after buying an additional 17,862 shares in the last quarter. Suntrust Banks Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $320,000. Parametric Portfolio Associates LLC grew its holdings in shares of Alnylam Pharmaceuticals by 8.2% during the second quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock valued at $5,180,000 after buying an additional 4,913 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Alnylam Pharmaceuticals by 59.1% during the second quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock valued at $14,311,000 after buying an additional 66,651 shares in the last quarter. Institutional investors and hedge funds own 88.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/09/bmo-capital-markets-trims-alnylam-pharmaceuticals-alny-target-price-to-160-00.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply